Neuropsychiatric Outcomes Associated With GLP-1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status
Diabetes, obesity & metabolism · 2026 Oct 25 · Baik SH, Baye F, Xian H et
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 24 20:00 ETSource: Diabetes, obesity & metabolism
From the source
Read at pubmed.ncbi.nlm.nih.govNeuropsychiatric Outcomes Associated With GLP-1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status
Diabetes, obesity & metabolism · 2026 Oct 25 · Baik SH, Baye F, Xian H et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42928425/
